🔬 Explore the vital role of #Biostatistics in #clinicaltrials! 🇸🇪 Sweden and 🇳🇴 Norway lead the way in linking medicine and data. Dive into this fascinating article by @LinkMedical 📊 https://t.co/3gEmvSQK9E

Why early integration of #biometrics is crucial in planning, executing, and interpreting clinical trials effectively.

https://t.co/6sRahXIMhf We proudly share our latest article written by Maria Bertilsson together with the Biometrics team and @Labiotech_eu #biometrics #datamanagement

CNS Clinical trial challenges and innovative solutions https://t.co/hlhREX9Lax #CNS #clinicaltrials #innovation

We are very happy about the positive results for @AlzeCure Pharma read the news on @NLifeScience https://t.co/NAZR5vD2Fx #clinicaltrials #collaborations #innovation

Positive Results for @AlzeCure's Phase IIa clinical study in neuropathic pain with the non-opioid ACD440 https://t.co/QWLHoIvIC9

Lipigon Pharmaceuticals AB chooses LINK Medical, a Nordic CRO for the planning & design of their clinical phase II study with Lipisense. The study aims to study safety & treatment effects in patients with severely elevated levels of blood fat triglyceride https://t.co/zHP7VRTVOK

Redeye endorses, based on the recent news that Alzecure has presented, the positive phase IIa data with ACD440 in neuropathic pain. We give our initial take and raise our base case Read the article here https://t.co/FqSRLuLGdd #alzecure #ACD440 #redeye #TRPV1 #neuropathicpain

Meet our colleagues and join our Summer Mingle with a lecture on how to prepare for inspections with Gunnar Danielsson and Philip Lange Møller. Two former GCP inspectors & clinical study experts. May 24 #Copenhagen #GCP #Inspections #clinicalstudies https://t.co/d52QHREwgV

Save your spot at our Summer Mingle, May 24th in Copenhagen! https://t.co/cPvCauINoz #clinicaldevelopment #GCP #inspections

The strong beginning of 2023, with significant success in our projects, strengthens us in our work to develop innovative, groundbreaking drugs in the fields of Alzheimer’s disease, pain and other severe diseases,” says Martin Jönsson, CEO. More: https://t.co/D2wdFWWDPT

Save your spot. This event was fully booked the last time we had Gunnar and Philip together. #denmark https://t.co/cPvCauINoz #GCP #Inspections #biotech #medTech #pharma

Join our free summer mingle event and attend a lecture with two senior advisors experienced as GCP inspectors. Save your spot! #denmark https://t.co/cPvCauINoz

Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe https://t.co/aVRtS3XHYJ

#LINKteams #MarketAccess learn more on how LINK Medical can provide strategic Market Access advice for your product, and support you with Health Economic solutions. https://t.co/qUpWqGa1hR

Last Patient Last Visit (LPLV) Milestone achieved for AlzeCure’s phase II clinical trial of the non-opioid ACD440 in neuropathic pain https://t.co/fH3VLqbWsf

Positive progress for AlzeCure's First-in-Class non-opioid against neuropathic pain. - Phase II results expected latest this summer https://t.co/kQ6mcvyOTz

https://t.co/u5oyON0Kyo We are honored and want to congratulate our #LINKteams and #Imcyse for the opportunity to support this very important study that can make a significant difference in patients with type 1 diabetes” - Sissel Lønning Andresen

Expert Insight for Quality Drug Development Using a TPP as a map lets you understand what you need to achieve for your product to be successful. Product development is not just about doing things right, it is about doing the right things. #GCP #TPP https://t.co/1p8a0BTsvG

AlzeCure’s neuropathic pain candidate study reaches crucial phase https://t.co/x8BQO9OXR9 @AlzeCure #neuropathicpain #ACD440 #nonopioiddrug #peripheralneuropathicpain #phase2research #gel #transdermalgel #skin #TRPV1antagonist @LINKMedical #LINKMedicalResearch